This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: March 8, 2002
Last updated: January 16, 2013
Last verified: January 2013
This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

Condition Intervention Phase
Cervical Squamous Cell Carcinoma Recurrent Cervical Cancer Drug: erlotinib hydrochloride Other: laboratory biomarker analysis Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: At 6 months ]
  • Frequency and severity of adverse effects as measured by NCI CTC version 3.0 [ Time Frame: Up to 5 years ]

Secondary Outcome Measures:
  • Duration of overall survival [ Time Frame: Up to 5 years ]
  • Duration of progression-free survival [ Time Frame: Up to 5 years ]
  • Frequency of clinical response (complete and partial) [ Time Frame: Up to 5 years ]
  • Prognostic factors including initial performance status and age [ Time Frame: Up to 5 years ]

Enrollment: 51
Study Start Date: March 2002
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (erlotinib hydrochloride)
Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: erlotinib hydrochloride
Given PO
Other Names:
  • CP-358,774
  • erlotinib
  • OSI-774
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. To evaluate the antitumor cytostatic activity of OSI-774 as measured by the probability of surviving progression-free for at least 6 months in patients with persistent or recurrent squamous cell carcinoma of the cervix.

II. To determine the nature and degree of toxicity of OSI-774 in this cohort of patients.


I. To determine the partial and complete response rates in patients with squamous cell carcinoma of the cervix receiving OSI-774.

II. To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774.

III. Assess the effects of prognostic factors: initial performance status and age.


I. To determine epidermal growth factor receptor (EGFR) and p110 truncated EGFR (p110 sEGFR) isoform expression levels in primary tumors, and from tumor samples obtained pretreatment and following four weeks of therapy to determine tumor response (or resistance) to OSI-774 inhibition of the EGFR tyrosine kinase.

II. To correlate EGFR and p110sEGFR expression levels with either MAPK or AKT phosphorylation status in the same tissue samples obtained pretreatment and following four weeks of drug treatment to determine downstream effects with response to OSI-774 inhibition of EGFR.

III. To determine whether pretreatment serum p110 sEGFR concentrations are a useful prognostic indicator and whether altered and/or sEGFR concentrations are useful indicators of therapeutic responsiveness, time to progression, and overall survival in cervical carcinoma patients.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed squamous cell carcinoma (SCC) of the cervix

    • Persistent or recurrent progressive disease
    • At least 1 prior systemic chemotherapy regimen for management of advanced, metastatic, or recurrent SCC of the cervix is required

      • Chemotherapy administered as a radiosensitizer in conjunction with radiotherapy does not count as a systemic chemotherapy regimen
  • At least 1 unidimensionally measurable target lesion

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
    • Lesions within a previously irradiated field are considered nontarget lesions unless disease progression or persistence is confirmed ≥ 90 days after completion of radiotherapy
  • Tumor accessible for repeat needle biopsy
  • Ineligible for a higher priority Gynecologic Oncology Group (GOG) protocol (any active GOG phase III protocol for the same patient population)
  • Performance status - GOG 0-2 (for patients who have received only 1 prior regimen)
  • Performance status - GOG 0-1 (for patients who have received 2 prior regimens)
  • Platelet count at least 100,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Bilirubin no greater than upper limit of normal (ULN)
  • SGOT no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • Creatinine no greater than 1.5 times ULN
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No abnormalities of the cornea (e.g., dry eye syndrome or Sjogren's syndrome)
  • No congenital abnormalities (e.g., Fuch's dystrophy)
  • No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
  • No abnormal corneal sensitivity test (Schirmer test or similar tear production test)
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • No uncontrolled concurrent illness
  • No ongoing or active infection requiring IV antibiotics
  • No psychiatric illness or social situation that would preclude study compliance
  • No grade 2 or greater sensory or motor neuropathy
  • No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • At least 3 weeks since prior immunologic therapy for SCC of the cervix
  • One additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease allowed
  • At least 3 weeks since prior chemotherapy for SCC of the cervix and recovered
  • No prior non-cytotoxic chemotherapy for recurrent or persistent disease
  • At least 3 weeks since prior hormonal therapy for SCC of the cervix
  • At least 3 weeks since prior radiotherapy for SCC of the cervix and recovered
  • Recovered from recent prior surgery
  • At least 3 weeks since other prior therapy for SCC of the cervix
  • No prior epidermal growth factor receptor-targeting therapies
  • No prior anticancer treatment that would preclude study participation
  • No other concurrent investigational or commercial agents or therapies for SCC of the cervix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00031993

United States, Pennsylvania
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States, 19103
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Russell Schilder Gynecologic Oncology Group
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00031993     History of Changes
Other Study ID Numbers: NCI-2012-02457
U10CA027469 ( U.S. NIH Grant/Contract )
CDR0000069247 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: March 8, 2002
Last Updated: January 16, 2013

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Uterine Cervical Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 20, 2017